

Hansa Medical

Bulletin from the Extraordinary General Meeting of Hansa Medical AB

On October 29, 2018, Hansa Medical AB (NASDAQ Stockholm: HMED) held an extraordinary general meeting. The following resolution was passed at the general meeting.

Approval of the board's proposal to authorize the board to resolve on new issues of ordinary shares

The general meeting resolved to authorize the board, for the period up to the next annual general meeting, to adopt decisions, whether on one or several occasions and whether with or without preemptive rights for the shareholders, to issue new common shares, provided that such issues, in aggregate, must not exceed ten percent of the total number of outstanding common shares in the Company as of the date of the extraordinary general meeting.

The purpose of the authorization is to increase the financial flexibility of the Company and the acting scope of the board of directors, as well as to potentially broaden the shareholder base.

The information was submitted for publication, through the agency of the contact person set out below, on October 29, 2018 at 11:00am CET.

About Hansa Medical

Hansa Medical (NASDAQ Stockholm:HMED) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company's lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.

For further information, please contact:

Company:

Emanuel Björne, Vice President Business Development and Investor Relations
Hansa Medical AB (Publ)
Mobile: +46707175477
E-mail: emanuel.bjorne@hansamedical.com
www.hansamedical.com

Swedish Investor and Media Relations:

Cord Communications
Mikael Widell
+46 70-311 99 60

U.K. Investor and Media Relations

FTI Consulting
Simon Conway/ Stephanie Cuthbert
+44 (0)20 3727 1000

U.S. Investor and Media Relations:

Argot Partners
Stephanie Marks / David Rosen (media)
+1 212 600 1902